



BIOCURE TECHNOLOGY INC. ANNOUNCES UNIT FINANCING

VANCOUVER, British Columbia – April 21, 2025 – Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) is pleased to announce a non-brokered private placement financing of up to 7,500,000 units (each a “Unit”) at \$0.02 per Unit of the Company for aggregate proceeds of up to CAD\$150,000 (the “Offering”).

Each Unit will consist of one (1) common share (a “Share”) in the capital of the Company and one transferrable common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Share (a “Warrant Share”) at a price of \$0.05 for a period of five (5) years from the date of issuance.

Proceeds from the Offering will be used for administrative and general working purposes. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.

No new insiders or control persons are expected to be created as a result of the Placement. Existing insiders of the Company may participate in the Offering, and such participation constitutes a “related party transaction”, as defined in Multilateral Instrument 61-101-- Protection of Minority Security Holders (“MI 61-101”) in Special Transactions. The Company expects to rely on exemptions from the formal valuation requirements of MI 61-101, pursuant to Subsection 5.5(b) of MI-61-101 (as the Company’s common shares are listed only on the CSE), and from the minority shareholder approval requirements of MI 61-101, pursuant to Subsection 5.7(1)(a) of MI 61-101 (as neither the fair market value of the Units to be issued to insiders nor the consideration to be paid by insiders pursuant to the Placement is expected to exceed 25 per cent of the Company’s market capitalization, as determined in accordance with MI 61-101).

The financing previously announced on December 19, 2024, has been cancelled.

/s/ “SIMON CHENG”
CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding

funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements.

Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.